Pfizer's retired NASH drug shown to reduce liver fat, inspiring new faith in the DGAT2 pathway
Nearly two years ago, Pfizer sent a NASH drug to the freezer because it didn’t appear viable long-term. Now, scientists for the pharma giant say the drug reduces liver fat, and a different version of that therapy may yet see daylight as part of a partnership with Novartis.
In a study published in Science Translational Medicine, Pfizer scientists reported that PF-06427878, a DGAT2 inhibitor, reduced fat and lipogenic gene expression in mouse and rat studies. That triggered small clinical trials, where volunteers in the drug arm saw a 31.5% reduction in liver fat after 14 days and minimal adverse effects.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
